Nektar Therapeutics Stock Debt To Equity

NKTR Stock

USD 0.89 0.02 2.20%

Nektar Therapeutics fundamentals help investors to digest information that contributes to Nektar Therapeutics' financial success or failures. It also enables traders to predict the movement of Nektar Stock. The fundamental analysis module provides a way to measure Nektar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nektar Therapeutics stock.

		Last Reported	Projected for Next Year
	Debt To Equity	0.81	0.77

As of 01/21/2025, Debt To Equity is likely to drop to 0.77.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Nektar Therapeutics Company Debt To Equity Analysis

Nektar Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Nektar Therapeutics Debt To Equity

0.33 %

Most of Nektar Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nektar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Nektar Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Nektar Therapeutics is extremely important. It helps to project a fair market value of Nektar Stock properly, considering its historical fundamentals such as Debt To Equity. Since Nektar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nektar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nektar Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Current Deferred Revenue	Short Term Investments	Common Stock	Net Receivables	Long Term Debt	Property Plant Equipment	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	0.07	-0.05	0.59	0.5	0.99	0.49	-0.15	0.99	-0.34	0.92	0.18	-0.16	0.06	-0.6	0.94	0.43	0.49	-0.52	0.74	0.42	0.94	0.96	-0.11
Total Stockholder Equity	0.98		-0.06	0.02	0.57	0.31	0.97	0.45	-0.22	0.97	-0.18	0.91	0.28	-0.1	0.12	-0.53	0.98	0.38	0.53	-0.49	0.8	0.4	0.96	0.99	-0.09
Net Debt	0.07	-0.06		-0.03	-0.15	0.52	0.03	0.56	0.32	0.07	-0.38	-0.02	-0.27	-0.17	-0.09	-0.03	-0.1	0.09	-0.21	-0.02	-0.04	0.09	0.01	-0.15	-0.22
Retained Earnings	-0.05	0.02	-0.03		-0.49	-0.2	-0.11	0.15	0.66	-0.09	0.64	0.1	-0.1	-0.14	0.79	0.81	-0.06	-0.7	-0.72	0.74	0.47	-0.67	0.24	0.06	-0.74
Accounts Payable	0.59	0.57	-0.15	-0.49		0.31	0.65	0.31	-0.56	0.64	-0.33	0.49	0.24	-0.04	-0.26	-0.7	0.59	0.52	0.72	-0.64	0.04	0.5	0.42	0.57	0.36
Total Liab	0.5	0.31	0.52	-0.2	0.31		0.47	0.36	0.34	0.44	-0.81	0.46	-0.35	-0.32	-0.06	-0.44	0.19	0.4	0.01	-0.23	0.09	0.18	0.36	0.32	-0.25
Total Current Assets	0.99	0.97	0.03	-0.11	0.65	0.47		0.43	-0.23	0.99	-0.33	0.92	0.27	-0.14	0.03	-0.63	0.94	0.51	0.56	-0.59	0.68	0.49	0.92	0.96	-0.04
Short Term Debt	0.49	0.45	0.56	0.15	0.31	0.36	0.43		0.08	0.47	-0.19	0.3	-0.37	-0.12	0.08	-0.19	0.41	-0.18	0.03	0.05	0.4	-0.08	0.46	0.36	-0.22
Current Deferred Revenue	-0.15	-0.22	0.32	0.66	-0.56	0.34	-0.23	0.08		-0.25	-0.03	-0.04	-0.5	-0.47	0.51	0.6	-0.36	-0.44	-0.83	0.66	0.19	-0.63	0.03	-0.17	-0.8
Short Term Investments	0.99	0.97	0.07	-0.09	0.64	0.44	0.99	0.47	-0.25		-0.28	0.9	0.3	-0.08	0.04	-0.61	0.95	0.48	0.56	-0.58	0.69	0.48	0.93	0.95	-0.04
Common Stock	-0.34	-0.18	-0.38	0.64	-0.33	-0.81	-0.33	-0.19	-0.03	-0.28		-0.21	0.39	0.28	0.5	0.72	-0.12	-0.57	-0.3	0.46	0.11	-0.38	-0.1	-0.15	-0.17
Net Receivables	0.92	0.91	-0.02	0.1	0.49	0.46	0.92	0.3	-0.04	0.9	-0.21		0.33	-0.13	0.24	-0.4	0.84	0.44	0.37	-0.41	0.7	0.42	0.91	0.93	-0.24
Long Term Debt	0.18	0.28	-0.27	-0.1	0.24	-0.35	0.27	-0.37	-0.5	0.3	0.39	0.33		0.17	0.07	-0.07	0.35	0.52	0.47	-0.53	0.11	0.61	0.24	0.31	0.19
Property Plant Equipment	-0.16	-0.1	-0.17	-0.14	-0.04	-0.32	-0.14	-0.12	-0.47	-0.08	0.28	-0.13	0.17		0.09	0.01	-0.07	-0.11	0.2	0.02	-0.25	-0.02	-0.19	-0.08	0.3
Good Will	0.06	0.12	-0.09	0.79	-0.26	-0.06	0.03	0.08	0.51	0.04	0.5	0.24	0.07	0.09		0.66	-0.04	-0.46	-0.52	0.53	0.31	-0.5	0.3	0.2	-0.77
Intangible Assets	-0.6	-0.53	-0.03	0.81	-0.7	-0.44	-0.63	-0.19	0.6	-0.61	0.72	-0.4	-0.07	0.01	0.66		-0.58	-0.73	-0.83	0.83	-0.07	-0.71	-0.33	-0.48	-0.58
Net Tangible Assets	0.94	0.98	-0.1	-0.06	0.59	0.19	0.94	0.41	-0.36	0.95	-0.12	0.84	0.35	-0.07	-0.04	-0.58		0.39	0.61	-0.56	0.77	0.47	0.9	0.95	0.07
Long Term Debt Total	0.43	0.38	0.09	-0.7	0.52	0.4	0.51	-0.18	-0.44	0.48	-0.57	0.44	0.52	-0.11	-0.46	-0.73	0.39		0.74	-0.89	-0.03	0.91	0.26	0.37	0.42
Capital Surpluse	0.49	0.53	-0.21	-0.72	0.72	0.01	0.56	0.03	-0.83	0.56	-0.3	0.37	0.47	0.2	-0.52	-0.83	0.61	0.74		-0.86	0.08	0.8	0.31	0.49	0.71
Deferred Long Term Liab	-0.52	-0.49	-0.02	0.74	-0.64	-0.23	-0.59	0.05	0.66	-0.58	0.46	-0.41	-0.53	0.02	0.53	0.83	-0.56	-0.89	-0.86		-0.05	-0.91	-0.32	-0.46	-0.55
Long Term Investments	0.74	0.8	-0.04	0.47	0.04	0.09	0.68	0.4	0.19	0.69	0.11	0.7	0.11	-0.25	0.31	-0.07	0.77	-0.03	0.08	-0.05		0.03	0.87	0.79	-0.38
Short Long Term Debt	0.42	0.4	0.09	-0.67	0.5	0.18	0.49	-0.08	-0.63	0.48	-0.38	0.42	0.61	-0.02	-0.5	-0.71	0.47	0.91	0.8	-0.91	0.03		0.24	0.36	0.55
Net Invested Capital	0.94	0.96	0.01	0.24	0.42	0.36	0.92	0.46	0.03	0.93	-0.1	0.91	0.24	-0.19	0.3	-0.33	0.9	0.26	0.31	-0.32	0.87	0.24		0.96	-0.32
Net Working Capital	0.96	0.99	-0.15	0.06	0.57	0.32	0.96	0.36	-0.17	0.95	-0.15	0.93	0.31	-0.08	0.2	-0.48	0.95	0.37	0.49	-0.46	0.79	0.36	0.96		-0.14
Capital Stock	-0.11	-0.09	-0.22	-0.74	0.36	-0.25	-0.04	-0.22	-0.8	-0.04	-0.17	-0.24	0.19	0.3	-0.77	-0.58	0.07	0.42	0.71	-0.55	-0.38	0.55	-0.32	-0.14

Click cells to compare fundamentals

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Nektar Therapeutics

Debt To Equity Over Time

Nektar Total Stockholder Equity

Total Stockholder Equity

143.1 Million

At this time, Nektar Therapeutics' Total Stockholder Equity is relatively stable compared to the past year.

According to the company disclosure, Nektar Therapeutics has a Debt To Equity of 0.326%. This is 99.39% lower than that of the Pharmaceuticals sector and 98.32% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.33% higher than that of the company.

Nektar Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nektar Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nektar Therapeutics could also be used in its relative valuation, which is a method of valuing Nektar Therapeutics by comparing valuation metrics of similar companies.

Nektar Therapeutics is currently under evaluation in debt to equity category among its peers.

Nektar Fundamentals

	Return On Equity	-1.62
	Return On Asset	-0.23
	Profit Margin	(1.81) %
	Operating Margin	(1.42) %
	Current Valuation	28.3 M
	Shares Outstanding	184.46 M
	Shares Owned By Insiders	1.29 %
	Shares Owned By Institutions	76.59 %
	Number Of Shares Shorted	4.35 M
	Price To Earning	8.02 X
	Price To Book	3.37 X
	Price To Sales	1.77 X
	Revenue	90.12 M
	Gross Profit	63.15 M
	EBITDA	(243.11 M)
	Net Income	(276.06 M)
	Cash And Equivalents	546.39 M
	Cash Per Share	2.91 X
	Total Debt	117.78 M
	Debt To Equity	0.33 %
	Current Ratio	7.14 X
	Book Value Per Share	0.27 X
	Cash Flow From Operations	(192.61 M)
	Short Ratio	2.26 X
	Earnings Per Share	(0.84) X
	Price To Earnings To Growth	3.22 X
	Target Price	4.56
	Number Of Employees	137
	Beta	0.61
	Market Capitalization	164.54 M
	Total Asset	398.03 M
	Retained Earnings	(3.48 B)
	Working Capital	279.43 M
	Current Asset	350.05 M
	Current Liabilities	61.25 M
	Net Asset	398.03 M

About Nektar Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Nektar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nektar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nektar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Nektar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nektar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nektar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Nektar Stock

0.63	AZN	AstraZeneca PLC ADR	Pair Corr
0.84	GSK	GlaxoSmithKline PLC ADR Sell-off Trend	Pair Corr
0.86	NVS	Novartis AG ADR	Pair Corr

Moving against Nektar Stock

0.69	MBFJF	Mitsubishi UFJ Financial	Pair Corr
0.57	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.39	GILD	Gilead Sciences	Pair Corr
0.35	LH	Laboratory	Pair Corr

The ability to find closely correlated positions to Nektar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nektar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nektar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nektar Therapeutics to buy it.

The correlation of Nektar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nektar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nektar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Nektar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Nektar Stock Analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC